Browse Studies — Arctuva

Phase 3

A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participant…

ObesityOverweightChronic Weight Management+1 more

Estimated

~$10 – $8,750

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07654374

Phase 3

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safet…

ObesityOverweightChronic Weight Management+1 more

Estimated

~$10 – $8,750

Ascletis Pharma (China) Co., LimitedNCT07743450

Phase 3

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)

Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safet…

ObesityOverweightChronic Weight Management

Estimated

~$10 – $8,750

Ascletis Pharma (China) Co., LimitedNCT07743463

Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety,…

ObesityOverweightChronic Weight Management

Estimated

~$10 – $8,750

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07654361